Figure S2 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Vignesh Narasimhan(Peter MacCallum Cancer Centre), Susan L. Woods(South Australian Health and Medical Research Institute), Josephine A. Wright, Gayle X.Y. Tye(The University of Adelaide), G. Adam Whitney(Precision for Medicine (United States)), Michael P. Flood(Peter MacCallum Cancer Centre), Alexander G. Heriot(Peter MacCallum Cancer Centre), Robert G. Ramsay, Julie Marker(SA Health), Peter J. Hewett(Basil Hetzel Institute), Anne B. Richardson(Precision for Medicine (United States)), Tamsin R.M. Lannagan(South Australian Health and Medical Research Institute), Michael Churchill(Harvard University), Timothy Price(Basil Hetzel Institute), Hiroki Kobayashi(Columbia University Irving Medical Center), Carla Grandori(Precision for Medicine (United States)), Jeanne Tie(The Royal Melbourne Hospital), Rachele Rosati(Precision for Medicine (United States)), Shalini Pereira, Siddhartha Mukherjee(NewYork–Presbyterian Hospital), Michael Michael(Ospedale San Donato), Daniel L. Worthley(Brisbane Hand & Upper Limb Research Institute), Tongtong Wang(Shandong Agricultural University), Laura Vrbanac(The University of Adelaide)
Cited by 0
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k